oral semaglutide approval Novo Nordisk has announced that the FDA has approved the Wegovy® pill (once-daily 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults US regulators approve Wegovy pill,

We combine expert clinical reasoning, hands-on care, strength programming, and (when appropriate) education on peptides and performance toolsbased on what you need, not a one-size-fits-all approach

Semaglutide is typically prescribed for individuals with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, such as type 2 diabetes, high blood pressure, or high cholesterol

We connect you with licensed healthcare providers who specialize in metabolic health

Get expert care from top-rated providers Find the right provider for your needs select your state to find expert care near you.